Capillary Film Technology (CFT), a technology and product development company for life sciences and clinical diagnostics, has received GBP98,000 in funding as part of a Small Business Research Initiative (SBRI) for Healthcare development contract. The funding will be used to develop a cost-effective and fully quantitative multiplexed point-of-care (PoC) testing technology to aid in the assessment of acute coronary syndrome (ACS).
The PoC diagnostic is based on CFT's FluorEx technology, a low-cost microfluidic fluoropolymer film that possesses unique optical transparency. FluorEx uses a parallel array of 10 x 200mcm capillaries to enable rapid fully quantitative immunoassays to be incorporated in existing or emergent diagnostic technologies. The technology has the potential to provide a cost-effective quantitative option for diagnosing ACS, resulting in reduced waiting times and improved treatment for patients. CFT's FluorEx technology is available for licensing.